Transvenous diaphragm neurostimulation reduces mechanical ventilation duration and increases weaning success, leading to cost savings and QALY gains in mechanically ventilated patients
Transvenous diaphragm neurostimulation (tDNS) was associated with a 2.8-day reduction in mechanical ventilation duration and a 10.5% increase in weaning success compared to standard of care. This led to projected acute care cost savings of $12,102 and long-term care savings of $11,999, with 0.10-0.68 QALYs gained over a patient's remaining lifetime.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Transvenous diaphragm neurostimulation reduces mechanical ventilation duration and increases weaning success, leading to cost savings and QALY gains in mechanically ventilated patients The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Transvenous diaphragm neurostimulation reduces mechanical ventilation duration and increases weaning success, leading to cost savings and QALY gains in mechanically ventilated patients
This conclusion is most relevant to: Mechanically ventilated patients in a U.S. acute hospital setting.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning. (Critical care medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸tDNS stimulates the diaphragm via transvenous electrode
- ▸Improves respiratory muscle function
- ▸Facilitates earlier weaning from mechanical ventilation
- ▸Reduces ventilation duration and associated complications, leading to cost savings and QALY gains
Who Might Benefit
Evidence fit by population:
- ▸Mechanically ventilated patients in a U.S. acute hospital setting
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Exploratory analysis based on a single randomized trial (RESCUE-3) and real-world claims data, not a definitive cost-effectiveness study
- ▸Lifetime projection model relies on assumptions that may not reflect real-world long-term outcomes
- ▸Therapy cost of tDNS was not included in the base case cost savings calculation
Frequently Asked Questions
What is transvenous diaphragm neurostimulation (tDNS)?▼
tDNS is a technique that uses a transvenous electrode to stimulate the phrenic nerve and diaphragm, aiming to improve respiratory muscle function and facilitate weaning from mechanical ventilation.
How much cost savings does tDNS provide in the acute setting?▼
Under base case assumptions, tDNS was projected to save $12,102 in acute hospital costs due to reduced mechanical ventilation duration.
What are the long-term benefits of tDNS for patients?▼
The study estimated that improved weaning with tDNS could lead to 0.10-0.68 quality-adjusted life-years (QALYs) gained over a patient's remaining lifetime.
Is tDNS cost-effective compared to standard of care?▼
The analysis suggests tDNS may be cost-effective and high-value, but definitive conclusions require future lifetime cost-effectiveness analyses that include the therapy cost.
References
- 1.Pietzsch JB, Ryschon AM, Mehta N, Ways JP, Ataya A, Criner GJ, Shrager JB. “Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning..” Critical care medicine, 2026. PMID: 42479503 DOI: 10.1097/CCM.0000000000007262